

### REMARKS

Claims 109-179 are pending in the application. Claims 109 and 113-117 have been amended. Claims 1-108 have been canceled without prejudice as directed to non-elected inventions. New claims 118-179 have been added. Support for the amendments and new claims can be found, e.g., in original claims 1-4, 25-39, 58, 59, and 85-87, and in the specification at, e.g., page 9, lines 11-17; page 11, line 10, to page 15, line 18; and page 67, lines 1-10. These amendments add no new matter.

Applicants thank the Examiner for the helpful telephone interview with the undersigned on March 16, 2005. In that interview, in response to a telephonic restriction requirement, applicants elected Group IV (claims 109-117). In addition, applicants elected the following species: SEQ ID NO:28 (amino acid sequence of a heavy chain of a human antibody; corresponds to gene segment 1-02); SEQ ID NO:30 (amino acid sequence of a light chain of a human antibody; corresponds to gene segment L5); and immune rejection accompanying transplantation of a tissue or organ in a subject.

Claims 109, 111-121, 123-126, 131, 133, 135, 137, 140, 143, 146, 149-152, 154-157, 162, 164, 166, 168, 171, 174, and 177 read on the elected species.

Applicants ask that all claims be examined in view of the amendment to the claims.

Applicant : Takashi Tsuji et al.  
Serial No. : 10/625,105  
Filed : July 22, 2003  
Page : 20 of 20

Attorney's Docket No.: 14539-006002 / JF-93US-D1

Please apply any charges or credits to deposit account 06-1050, referencing Attorney  
Docket No. 14539-006002.

Respectfully submitted,

Date: March 24, 2005

Jack Brennan  
Jack Brennan  
Reg. No. 47,443

Fish & Richardson P.C.  
Citigroup Center  
52nd Floor  
153 East 53rd Street  
New York, New York 10022-4611  
Telephone: (212) 765-5070  
Facsimile: (212) 258-2291

30223440.doc